Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting

Outline Slide Presented By Leora Horn at 2014 ASCO Annual Meeting

Slide 3 Presented By Leora Horn at 2014 ASCO Annual Meeting

LUX-Lung 3 and 6: design Presented By Leora Horn at 2014 ASCO Annual Meeting

Combined OS analysis: common mutations (n=631) Presented By Leora Horn at 2014 ASCO Annual Meeting

Combined OS analysis: mutation categories Presented By Leora Horn at 2014 ASCO Annual Meeting

JO25567 Study Design Presented By Leora Horn at 2014 ASCO Annual Meeting

Primary endpoint: PFS by independent review Presented By Leora Horn at 2014 ASCO Annual Meeting

PFS by EGFR Mutation Type Presented By Leora Horn at 2014 ASCO Annual Meeting

Acquired Resistance to EGFR TKIs Presented By Leora Horn at 2014 ASCO Annual Meeting

Phase I Trials With Third Generation EGFR Inhibitors Presented By Leora Horn at 2014 ASCO Annual Meeting

Phase I Trials Presented By Leora Horn at 2014 ASCO Annual Meeting

AZD9291: Response rate* in T790M+ (central test) Presented By Leora Horn at 2014 ASCO Annual Meeting

CO-1686: Best response in Phase 1 and early Phase 2 expansion cohort patients Presented By Leora Horn at 2014 ASCO Annual Meeting

HM61713: Response in T790M Cohort Presented By Leora Horn at 2014 ASCO Annual Meeting

RADIANT Trial Design Presented By Leora Horn at 2014 ASCO Annual Meeting

Disease-free Survival KM Plot – FAS Presented By Leora Horn at 2014 ASCO Annual Meeting

Slide 18 Presented By Leora Horn at 2014 ASCO Annual Meeting

Slide 19 Presented By Leora Horn at 2014 ASCO Annual Meeting

Summary Presented By Leora Horn at 2014 ASCO Annual Meeting

PROFILE 1014 Study Design Presented By Leora Horn at 2014 ASCO Annual Meeting

Primary Endpoint Met: Crizotinib Superior to Pemetrexed-based Chemotherapy in Prolonging PFSa Presented By Leora Horn at 2014 ASCO Annual Meeting

ASCEND-1 Study Design Presented By Leora Horn at 2014 ASCO Annual Meeting

Progression-Free Survival in Patients with ALK+ NSCLC Presented By Leora Horn at 2014 ASCO Annual Meeting

Summary Presented By Leora Horn at 2014 ASCO Annual Meeting

REVEL: Study Design Presented By Leora Horn at 2014 ASCO Annual Meeting

Overall Survival ITT Population Presented By Leora Horn at 2014 ASCO Annual Meeting

Study Design: Squire Presented By Leora Horn at 2014 ASCO Annual Meeting

Slide 29 Presented By Leora Horn at 2014 ASCO Annual Meeting

Summary Presented By Leora Horn at 2014 ASCO Annual Meeting

CREST Trial Design Presented By Leora Horn at 2014 ASCO Annual Meeting

Overall survival Presented By Leora Horn at 2014 ASCO Annual Meeting

PCI in SCLC: Trial Design Presented By Leora Horn at 2014 ASCO Annual Meeting

Time to Brain Metastasis Presented By Leora Horn at 2014 ASCO Annual Meeting

Overall Survival Presented By Leora Horn at 2014 ASCO Annual Meeting

Summary Presented By Leora Horn at 2014 ASCO Annual Meeting

KEYNOTE-001: First line therapy with MK3475 in patients with PD-L1 positive NSCLC Presented By Leora Horn at 2014 ASCO Annual Meeting

Antitumor Activity by MK-3475 Dose Presented By Leora Horn at 2014 ASCO Annual Meeting

Conclusions Presented By Leora Horn at 2014 ASCO Annual Meeting